Skip to main content

Advertisement

SpringerLink
Log in

Chronic Lymphocytic Leukemia: Inception to Cure: Are We There?

  • Review Article
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstract

There have been remarkable advances in our understanding of the biology and therapeutics of chronic lymphocytic leukemia. B cell receptor signaling and micro-environment in CLL biology have been the most modern areas of research. In CLL therapeutics, we have come a long way from alkylating agents to chemo-immunotherapy. Despite this there remain significant lacunae in the disease biology that has hindered our quest to achieve the ultimate in CLL: Cure. This review aims to summarize the past, present and future in the biology and treatment of CLL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Caligaris Cappio F (2009) Chronic lymphocytic leukemia: cinderella is becoming a star. Mol Med 15:67–69

    Article  PubMed  CAS  Google Scholar 

  2. Klein U, Dalla Favera R (2010) New insights into the pathogenesis of chronic lymphocytic leukemia. Semin Cancer Biol 20:377–383

    Article  PubMed  CAS  Google Scholar 

  3. Scarfò L, Dagklis A, Scielzo C, Fazi C, Ghia P (2010) CLL like monoclonal B-cell lymphocytosis: are we all bound to have it? Cancer Biol 20:384–390

    Article  Google Scholar 

  4. Kem W, Bacher U, Haferlach C, Dicker F et al (2012) Monoclonal B-cell lymphocytosis is closely related to chronic lymphocytic leukemia and may be better classified as early stage CLL. Br J Haematol 157:86–96

    Article  Google Scholar 

  5. Chiorazzi N, Rai KR, Ferrarini M (2005) Chronic lymphocytic leukemia. N Engl J Med 352:804–815

    Article  PubMed  CAS  Google Scholar 

  6. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F (2009) The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 114:3367–3375

    Article  PubMed  CAS  Google Scholar 

  7. Packham G, Stevenson S (2010) The role of B-cell receptor in the pathogenesis of chronic lymphocytic leukemia. Semin Cancer Biol 20:391–399

    Article  PubMed  CAS  Google Scholar 

  8. Pederson IM, Reed JC (2004) Microenvironmental interactions and survival of CLL B-cells. Leuk Lymphoma 45:2365–2372

    Article  Google Scholar 

  9. Herishanu Y, Perez-Galan P, Liu D et al (2011) The lymph-node microenvironment promotes B-cell receptor signaling, NF-kB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 117:563–574

    Article  PubMed  CAS  Google Scholar 

  10. Furman RR (2010) Prognostic markers and stratification of chronic lymphocytic leukemia. Hematology 2010:77–81

    Article  PubMed  Google Scholar 

  11. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46:219–234

    PubMed  CAS  Google Scholar 

  12. Binet JL, Auquier A, Dighiero G et al (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48:198–206

    Article  PubMed  CAS  Google Scholar 

  13. Hodgson K, Ferrer G, Montserrat E, Moreno C (2011) Chronic lymphocytic leukemia and autoimmunity: a systematic review. Haematologica 96:752–761

    Article  PubMed  CAS  Google Scholar 

  14. Molica S, Alberti A (1987) Prognostic value of lymphocyte doubling time in CLL. Cancer 60:2712–2716

    Article  PubMed  CAS  Google Scholar 

  15. Gentile M, Cutrona G, Neri A, Molica S, Ferrarini M, Morabito F (2009) Predictive value of beta2-microglobulin (beta2-m) levels in chronic lymphocytic leukemia since Binet A stages. Haematologica 94:887–888

    Article  PubMed  CAS  Google Scholar 

  16. Döhner H, Stilgenbauer S, Benner A et al (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910–1916

    Article  PubMed  Google Scholar 

  17. Oscier DG, Gardiner AC, Mould SJ et al (2002) Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 100:1177–1184

    PubMed  CAS  Google Scholar 

  18. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848–1854

    PubMed  CAS  Google Scholar 

  19. Orchard JA, Ibbotson RE, Davis Z et al (2004) ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 363:105–111

    Article  PubMed  CAS  Google Scholar 

  20. Crespo M, Bosch F, Villamor N et al (2003) ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348:1764–1775

    Article  PubMed  CAS  Google Scholar 

  21. Varma S, Lad D, Varma N, Sachdeva MUS, Bose P, Malhotra P (2011) Do regulatory T cells have a role in disease progression and autoimmune cytopenias of chronic lymphocytic leukemia? (Abstract). Blood 118:3864

    Google Scholar 

  22. Hallek M, Cheson BD, Catovsky D et al (2008) Guidelines for the diagnosis of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute Working Group 1996 guidelines. Blood 111:5446–5456

    Article  PubMed  CAS  Google Scholar 

  23. Altman SJ, Haut A, Cartwright GE, Wintrobe MM (1956) Early experience with p-(N,N-D1-2-chloroethyl) aminophenylbutyric acid (CB1348), a new chemotherapeutic agent effective in the treatment of chronic lymphocytic leukemia. Cancer 9:512–517

    Article  PubMed  CAS  Google Scholar 

  24. No authors cited (1999) Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists’ Collaborative Group. J Natl Cancer Inst 91:861–868

    Article  Google Scholar 

  25. Knauf WU, Lissichkov T, Aldaoud A et al (2009) Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27:4378–4384

    Article  PubMed  CAS  Google Scholar 

  26. Rai KR, Peterson BL, Appelbaum FR et al (2000) Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343:1750–1757

    Article  PubMed  CAS  Google Scholar 

  27. Rai KR, Hollweg A (2011) Fludarabine versus chlorambucil: is the debate over? Clin Lymphoma Myeloma Leuk 11:S7–S9

    Article  PubMed  Google Scholar 

  28. Eichhorst BF, Busch R, Stilgenbauer S et al (2009) First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 114:3382–3391

    Article  PubMed  CAS  Google Scholar 

  29. Eichhorst BF, Busch R, Hopfinger G et al (2006) German CLL Study Group. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107:885–891

    Article  PubMed  CAS  Google Scholar 

  30. Richards S, Steurer M, for the (CLLTCG) CLL Trialists Collaborative Group, UK (2012) Systematic review of purine analogue treatment for chronic lymphocytic leukemia: lessons for future trials. Haematologica 97:428–3696

    Article  CAS  Google Scholar 

  31. McLaughlin P, Grillo-López AJ, Link BK et al (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825–2833

    PubMed  CAS  Google Scholar 

  32. Itälä M, Geisler CH, Kimby E et al (2002) Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. Eur J Haematol 69:129–134

    Article  PubMed  Google Scholar 

  33. Hainsworth JD, Litchy S, Barton JH et al (2003) Minnie Pearl Cancer Research Network. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 21:1746–1751

    Article  PubMed  CAS  Google Scholar 

  34. Osterborg A, Dyer MJ, Bunjes D et al (1997) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 15:1567–1574

    PubMed  CAS  Google Scholar 

  35. Rai KR, Freter CE, Mercier RJ et al (2002) Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 20:3891–3897

    Article  PubMed  CAS  Google Scholar 

  36. Osterborg A, Mellstedt H, Keating M (2002) Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia. Med Oncol 19:S21–S26

    Article  PubMed  Google Scholar 

  37. Lundin J, Kimby E, Björkholm M et al (2002) Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100:768–773

    Article  PubMed  CAS  Google Scholar 

  38. Skoetz N, Bauer K, Elter T et al (2012) Alemtuzumab for patients with chronic lymphocytic leukaemia. Cochrane Database Syst Rev 2:CD008078

    PubMed  Google Scholar 

  39. Byrd JC, Peterson BL, Morrison VA et al (2003) Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101:6–14

    Article  PubMed  CAS  Google Scholar 

  40. Hallek M, Fischer K, Fingerle-Rowson G et al (2010) International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomized, open-label, phase 3 trial. Lancet 376:1164–1174

    Article  PubMed  CAS  Google Scholar 

  41. Fischer K, Cramer P, Busch R et al (2011) Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 29:3559–3566

    Article  PubMed  CAS  Google Scholar 

  42. Tam CS, Keating MJ (2010) Chemoimmunotherapy of chronic lymphocytic leukemia. Nat Rev Clin Oncol 7:521–532

    Article  PubMed  CAS  Google Scholar 

  43. Schetelig J, Thiede C, Bornhauser M et al (2003) Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 21:2747–2753

    Article  PubMed  CAS  Google Scholar 

  44. Malhotra P, Hogan WJ, Litzow MR et al (2008) Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years. Leuk Lymphoma 49:1724–1730

    Article  PubMed  CAS  Google Scholar 

  45. Sorror ML, Storer BE, Sandmaier BM et al (2008) Five-year follow- up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 26:4912–4920

    Article  PubMed  Google Scholar 

  46. Brown JR, Stevenson K, Kim HT et al (2008) Comparative outcome of myeloablative and reduced intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia. Blood 112:972

    Google Scholar 

  47. Dreger P, Corradini P, Kimby E et al (2007) Chronic leukemia working party of the EBMT. Indications for Allogeneic stem cell transplantation in CLL: the EBMT transplant consensus. Leukemia 21:12–17

    Article  PubMed  CAS  Google Scholar 

  48. Sutton L, Chevret S, Tournilhac O et al (2011) Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) and Groupe Français d’étude de la Leucémie Lymphoïde Chronique (GFLLC). Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC. Blood 117:6109–6119

    Article  PubMed  CAS  Google Scholar 

  49. Del Giudice I, Mauro FR, Foà R (2011) Chronic lymphocytic leukemia in less fit patients “slow-go’’. Leuk Lymphoma 52:2207–2216

    Article  PubMed  Google Scholar 

  50. Zent CS, Kay NE (2011) Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach. Leuk Lymphoma 52:1425–1434

    Article  PubMed  Google Scholar 

  51. Hallek M, Fischer K, Fingerle-Rowson G et al (2010) Addition of Rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia: a randomized, open label, phase 3 trial. Lancet 376:1164–1174

    Article  PubMed  CAS  Google Scholar 

  52. Fischer K, Cramer P, Stilgenbauer S et al (2009) Bendamustine combined with rituximab (BR) in first line therapy of advanced CLL: a multicenter phase II trial of the German CLL Study group (GCLLSG) (Abstract). Blood 114:89

    Google Scholar 

  53. Woyach JA, Ruppert AS, Heerema NA et al (2011) Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol 29:1349–1355

    Article  PubMed  CAS  Google Scholar 

  54. Knauf WU, Lissichkov T, Aldaoud A et al (2009) Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. Blood 114:3382–3391

    Article  Google Scholar 

  55. Foon KA, Boyiadzis M, Land SR et al (2009) Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27:498–503

    Article  PubMed  CAS  Google Scholar 

  56. Hillmen P, Gribben JG, Follows GA et al (2010) Rituximab plus chlorambucil in patients with CD20-positive B-cell chronic lymphocytic leukemia (CLL): final response analysis of an open-label phase II study (Abstract). Blood 116:697

    Google Scholar 

  57. Pitini V, Arrigo C, Naro C et al (2008) Subcutaneous low-dose alemtuzumab as first linetherapy for elderly CLL patients with deletion of 17p. J Clin Oncol 26:384s

    Google Scholar 

  58. Riches JC, Ramsay AG, Gribben JG (2010) T-cell function in chronic lymphocytic leukaemia. Semin Cancer Biol 20:431–438

    Article  PubMed  CAS  Google Scholar 

  59. Wendtner C, Hillmen P, Mahadevan D et al (2012) Final results of the phase I study of lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia (CLL-001 Study). Leuk Lymphoma 53:417–423

    Article  PubMed  CAS  Google Scholar 

  60. Wierda WG, Kipps TJ, Dürig J et al (2011) Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood 117:6450–6458

    Article  PubMed  CAS  Google Scholar 

  61. Morschhauser F, Cartron G, Lamy T et al (2009) Phase I study of RO5072759 (GA101) in relapsed/refractory CLL (Abstract). Blood 114:364

    Google Scholar 

  62. Furmann RR, Byrd JC, Brown JR et al (2010) CAL-101, an isoform selective inhibitor of phosphatidylinositol 3-kinase P110δ, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory CLL (Abstract). Blood 116:31

    Google Scholar 

  63. Burger JA, O-Brien S, Fowler N et al (2010) The Brutons tyrosine kinase inhibitor, PCI-32765, is well tolerated and demonstrates promising clinical activity in CLL and SLL: an update on ongoing phase 1 studies (Abstract). Blood 116:32

    Article  Google Scholar 

  64. Lanasa MC, Andritsos L, Brown JR et al (2010) Interim analysis of EFC6663, a multicenter phase 2 study of Alvocidib (Flavopiridol), demonstrates clinical responses among patients with Fludarabine refractory CLL (Abstract). Blood 116:32

    Google Scholar 

  65. Badoux XC, Keating MJ, Wang X et al (2011) Fludarabine, cyclophosphamide and rituximab chemoimmunotherapy is highly effective for relapsed patients with CLL. Blood 117:3016–3024

    Article  PubMed  CAS  Google Scholar 

  66. Stigenbauer S, Zenz T, Winkler D et al (2009) Subcutaneous alemtuzumab in fludarabine refractory chronic lymphocytic leukemia: clinical results and prognostic marker analysis from the CLL2H study of the German CLL study group. J Clin Oncol 27:3994–4001

    Article  Google Scholar 

  67. Ferrajoli A, Lee BN, Sclette EJ et al (2008) Lenalidomide induces complete and partial remissions in with relapsed and refractory CLL. Blood 111:5291–5297

    Article  PubMed  CAS  Google Scholar 

  68. Stilgenbauer S, Cymbalista F, Leblond V et al (2010) Subcutaneous Alemtuzumab combined with oral Dexamethasone, followed by Alemtuzumab maintenance or Allo-SCT in CLL with 17p or refractory to fludarabine: interim analysis of the CLL 20 trial of the GCLLSG and FCCLL/MW (Abstract). Blood 116:920

    Google Scholar 

  69. Castro JE, Sandoal-Sus JD, Bole J, Rassenti L, Kipps TJ (2008) Rituximab in combination with high dose methylprednisolone for the treatment of fludarabine refractory high risk chronic lymphocytic leukemia. Leukemia 22:2048–2053

    Article  PubMed  CAS  Google Scholar 

  70. Moreton P, Kennedy B, Lucas G et al (2005) Eradication of minimal residual disease in B-cell CLL after Alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23:2971–2979

    Article  PubMed  CAS  Google Scholar 

  71. Wendtner CM, Ritgen M, Schweighofer CD et al (2004) Consolidation with alemtuzumab in patients with CLL in first remission: experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL study group (GCLLSG). Leukemia 18:1093–1101

    Article  PubMed  CAS  Google Scholar 

  72. Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor: modified T-cells in chronic lymphocytic leukemia. N Engl J Med 365:725–733

    Article  PubMed  CAS  Google Scholar 

  73. Sadelain M, Brentjens R, Riviere (2009) The promise and pitfalls of chimeric antigen receptors. Curr Opin Immunol 21:215–223

    Article  PubMed  CAS  Google Scholar 

  74. June Ch, Blazar BR, Riley JL (2009) Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol 9:704–716

    Article  PubMed  CAS  Google Scholar 

  75. Lesterhuis WJ, Haanen JB, Punt CJ (2011) Cancer immunotherapy: revisited. Nat Rev Drug Dis 10:591–600

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India

    Deepesh P. Lad, Pankaj Malhotra & Subhash Varma

Authors
  1. Deepesh P. Lad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pankaj Malhotra
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Subhash Varma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pankaj Malhotra.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lad, D.P., Malhotra, P. & Varma, S. Chronic Lymphocytic Leukemia: Inception to Cure: Are We There?. Indian J Hematol Blood Transfus 29, 1–10 (2013). https://doi.org/10.1007/s12288-012-0192-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-012-0192-5

Keywords

Search

Navigation